Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

Genetic Immunity, InPlay Completes Patient Enrollment In Phase II Trial Of DermaVir Patch HIV Immunotherapeutic Nanomedicine Lead Product Candidate
Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary"s premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
generic viagra online
Causes And Consequences - Caring For Patients With Intellectual Disability
Patients with developmental disabilities such as Down syndrome or cerebral palsy will benefit from a new online learning activity launched today by The Royal Australian College of General Practitioners (RACGP) to assist GPs to navigate the complex area of developmental disability.
News of the day
Brain Energy Use Key To Understanding Consciousness, Yale Researchers Find
High levels of brain energy are required to maintain consciousness, a finding which suggests a new way to understand the properties of this still mysterious state of being, Yale University researchers report.
Health Insurance

BioAlliance Pharma Obtains European Approval For Loramyc(R) Tablet Embossing And Extension Of Its Shelf Life To 36 Months

BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on therapy and supportive care in cancer and AIDS, announced Europe-wide approval for embossing its Loramyc® mucoadhesive buccal tablet, developed for the treatment of oropharyngeal candidiasis. The embossing process has thus been approved under the Mutual Recognition Procedure; it was first required for the US market, where BioAlliance Pharma submitted a new drug application for Loramyc® to the Food and Drug Administration (FDA) in June 2009. BioAlliance Pharma will be able to harmonize Loramyc® production within those two key markets. BioAlliance Pharma also received European approval for extension of Loramyc®"s shelf life from 18 to 36 months. These two key industrial parameters are complementary assets for Loramyc® and will help optimizing manufacturing, storage and distribution costs. BioAlliance Pharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009